Drug intelligence / Profile preview

SPARC1613

Development stage: Phase 1
Lead developer: SPARC
Modality: Small Molecules
Administration: Intravenous

Overview

SPARC1613 is a small molecule chemotherapeutic agent with a wide spectrum of anti-tumor activity. It has been investigated primarily for the treatment of advanced carcinomas, especially breast cancer. The drug is administered intravenously and has undergone Phase 1 clinical trials in patients with locally recurrent or metastatic breast cancer. The precise mechanism of action for SPARC1613 remains unknown, but it is classified as a cytotoxic chemotherapy agent[1][2][3][4].

Other names: reference1613reference-1613reference 1613

Beyond the preview

Go deeper on SPARC1613.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPARC1613.

Explore the full profile